Jörg Vollmer joins Abalos Therapeutics with expertise in immunology, oncology, and infectious diseases, gained through roles at Rigontec GmbH, where he advanced immuno-oncology treatments and led R&D efforts.
Sebastian manages investments in immuno-oncology, regenerative medicine, and infectious diseases at the Boehringer Ingelheim Venture Fund, with 15+ years in drug discovery and pharmaceutical science.
Gerben Moolhuizen brings over three decades of experience in drug development across biotech and pharmaceutical industries, including leadership roles at ISA Pharmaceuticals and OctoPlus.
Abalos Therapeutics is supported by a syndicate of prestigious life science investors including Boehringer Ingelheim Venture Funds, High-Tech Gründerfonds, NRW.Bank and Gründerfonds Ruhr.
Abalos Therapeutics develops treatments that activate multiple immune system components to expose cancer cells and reduce tumors, using platform technologies to create drug candidates targeting systemic inflammation.